Skip to main content
Search
Search
    Quick Search anywhere
    Quick search in Citations
Advanced Search
Skip main navigationClose Drawer MenuOpen Drawer Menu
Previous article
Next article
Original Articles and Reviews

New Insights Into the Clinical and Nonclinical Effects of Psychedelic Substances

An Integrative Review

Published Online:September 17, 2021https://doi.org/10.1027/1016-9040/a000447

Abstract

Abstract. After decades of stagnation, research on psychedelic substances (such as lysergic acid diethylamide [LSD], psilocybin, or N,N-dimethyltryptamine [DMT]) has experienced a renaissance over the last 10 years, with various major research programs being conducted across Europe and the United States. This research primarily investigates the potential of psychedelics in the treatment of mental health disorders, their short- and long-term effects on recreational users, and the neurological and cognitive processes responsible for their effects. The present review provides a concise summary of the most recent insights gained from this research. We briefly outline the history of psychedelic research, the objective and subjective effects caused by these substances, the prevalence and socio-psychological correlates of their use, as well as their potential for harm. Subsequently, we review empirical research on the beneficial effects of psychedelics in clinical samples, focusing on their efficacy in the treatment of major depression, anxiety, and substance use disorders, and discuss research on the proposed neural and cognitive mechanisms behind these effects. We then review research on their effects on healthy subjects, focusing on psychological well-being as well as changes in personality, nature-relatedness, and creativity. Finally, we review empirical evidence regarding the long-term effects of single experiences with psychedelics and conclude with a summary and outlook.

References

  • Abraham, H. D., Aldridge, A. M., & Gogia, P. (1996). The psychopharmacology of hallucinogens. Neuropsychopharmacology, 14, 285–298. https://doi.org/10.1016/0893-133x(95)00136-2 First citation in articleCrossref, Google Scholar

  • Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020). Long-term effects of psychedelic drugs: A systematic review. Neuroscience and Biobehavioral Reviews, 113, 179–189. https://doi.org/10.1016/j.neubiorev.2020.03.017 First citation in articleCrossref, Google Scholar

  • Argento, E., Strathdee, S. A., Tupper, K., Braschel, M., Wood, E., & Shannon, K. (2017). Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting. BMJ Open, 7, Article e016025. https://doi.org/10.1136/bmjopen-2017-016025 First citation in articleCrossref, Google Scholar

  • Argento, E., Tupper, K. W., & Socias, M. E. (2019). The tripping point: The potential role of psychedelic-assisted therapy in the response to the opioid crisis. International Journal of Drug Policy, 66, 80–81. First citation in articleCrossref, Google Scholar

  • Barrett, F. S., & Griffiths, R. R. (2017). Classic hallucinogens and mystical experiences: phenomenology and neural correlates. In A. HalberstadtF. X. VollenweiderD. E. NicholsEds., Behavioral neurobiology of psychedelic drugs (pp. 393–430). Springer. First citation in articleCrossref, Google Scholar

  • Barrett, F. S., Carbonaro, T. M., Hurwitz, E., Johnson, M. W., & Griffiths, R. R. (2018). Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: Effects on cognition. Psychopharmacology, 235(10), 2915–2927. https://doi.org/10.1007/s00213-018-4981-x First citation in articleCrossref, Google Scholar

  • Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020). Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific Reports, 10(1), 1–14. https://doi.org/10.1038/s41598-020-59282-y First citation in articleCrossref, Google Scholar

  • Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015). Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology, 29, 1182–1190. https://doi.org/10.1177/0269881115609019 First citation in articleCrossref, Google Scholar

  • Barrett, F. S., Krimmel, S. R., Griffiths, R., Seminowicz, D. A., & Mathur, B. N. (2020). Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. NeuroImage, 218, Article 116980. https://doi.org/10.1016/j.neuroimage.2020.116980 First citation in articleCrossref, Google Scholar

  • Bogenschutz, M. P., & Johnson, M. W. (2016). Classic hallucinogens in the treatment of addictions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 64, 250–258. https://doi.org/10.1016/j.pnpbp.2015.03.002 First citation in articleCrossref, Google Scholar

  • Bogenschutz, M. P., & Pommy, J. M. (2012). Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: From indirect evidence to testable hypotheses. Drug Testing and Analysis, 4, 543–555. First citation in articleCrossref, Google Scholar

  • Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C. R., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29, 289–299. https://doi.org/10.1177/0269881114565144 First citation in articleCrossref, Google Scholar

  • Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30, 1268–1278. https://doi.org/10.1177/0269881116662634 First citation in articleCrossref, Google Scholar

  • Carhart-Harris, R. L., Bolstridge, M., Day, C., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Curran, H. V., & Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology, 235, 399–408. https://doi.org/10.1007/s00213-017-4771-x First citation in articleCrossref, Google Scholar

  • Carhart-Harris, R. L., Bolstridge, M., Rucker, J., & Day, C. M. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry, 3, 619–627. https://doi.org/10.1007/s00213-017-4771-x First citation in articleCrossref, Google Scholar

  • Carhart-Harris, R. L., Erritzoe, D., Haijen, E., Kaelen, M., & Watts, R. (2018). Psychedelics and connectedness. Psychopharmacology, 235, 547–550. https://doi.org/10.1007/s00213-017-4701-y First citation in articleCrossref, Google Scholar

  • Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., Hobden, P., Evans, J., Feilding, A., Wise, R. G., & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences of the United States of America, 109, 2138–2143. https://doi.org/10.1073/pnas.1119598109 First citation in articleCrossref, Google Scholar

  • Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018). Psychedelics and the essential importance of context. Journal of Psychopharmacology, 32, 725–731. https://doi.org/10.1177/0269881118754710 First citation in articleCrossref, Google Scholar

  • Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020). Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Journal of Contextual Behavioral Science, 15, 39–45. https://doi.org/10.1016/j.jcbs.2019.11.004 First citation in articleCrossref, Google Scholar

  • Davis, A. K., Clifton, J. M., Weaver, E. G., Hurwitz, E. S., Johnson, M. W., & Griffiths, R. R. (2020). Survey of entity encounter experiences occasioned by inhaled N, N-dimethyltryptamine: Phenomenology, interpretation, and enduring effects. Journal of Psychopharmacology, 34, 1008–1020. https://doi.org/10.1177/0269881120916143 First citation in articleCrossref, Google Scholar

  • Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., & Griffiths, R. R. (2019). 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. The American Journal of Drug and Alcohol Abuse, 45(2), 161–169. https://doi.org/10.1080/00952990.2018.1545024 First citation in articleCrossref, Google Scholar

  • Dolder, P. C., Schmid, Y., Müller, F., Borgwardt, S., & Liechti, M. E. (2016). LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology, 41(11), 2638–2646. https://doi.org/10.1038/npp.2016.82 First citation in articleCrossref, Google Scholar

  • Dos Santos, R. G., Sanches, R. F., Osório, F. D. L., & Hallak, J. E. (2018). Long-term effects of ayahuasca in patients with recurrent depression: A 5-year qualitative follow-up. Archives of Clinical Psychiatry (São Paulo), 45, 22–24. First citation in articleCrossref, Google Scholar

  • Earp, B. D. (2018). Psychedelic moral enhancement. Royal Institute of Philosophy Supplement, 83, 415–439. https://doi.org/10.1017/S1358246118000474 First citation in articleCrossref, Google Scholar

  • EMCDDA. (2012). Annual report 2012: The state of the drug problem in Europe. European Monitoring Centre for Drugs and Drug Addiction. First citation in articleGoogle Scholar

  • FDA. (2019). Breakthrough therapy. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy First citation in articleGoogle Scholar

  • Forstmann, M., & Sagioglou, C. (2017). Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness. Journal of Psychopharmacology, 31(8), 975–988. https://doi.org/10.1177/0269881117714049 First citation in articleCrossref, Google Scholar

  • Forstmann, M., Yudkin, D. A., Prosser, A. M., Heller, S. M., & Crockett, M. J. (2020). Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings. Proceedings of the National Academy of Sciences, 117(5), 2338–2346. https://doi.org/10.1073/pnas.1918477117 First citation in articleCrossref, Google Scholar

  • Frecska, E., Móré, C. E., Vargha, A., & Luna, L. E. (2012). Enhancement of creative expression and entoptic phenomena as after-effects of repeated ayahuasca ceremonies. Journal of Psychoactive Drugs, 44(3), 191–199. https://doi.org/10.1080/02791072.2012.703099 First citation in articleCrossref, Google Scholar

  • Gandy, S. (2019). Psychedelics and potential benefits in “healthy normals”: A review of the literature. Journal of Psychedelic Studies, 3(3), 280–287. https://doi.org/10.1556/2054.2019.029 First citation in articleCrossref, Google Scholar

  • Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology, 33(9), 1088–1101. https://doi.org/10.1177/0269881119845793 First citation in articleCrossref, Google Scholar

  • Garcia-Romeu, A., Griffiths, R. R., & Johnson, M. W. (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews, 7(3), 157–164. https://doi.org/10.2174/1874473708666150107121331 First citation in articleCrossref, Google Scholar

  • Gasser, P., Kirchner, K., & Passie, T. (2015). LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. Journal of Psychopharmacology, 29(1), 57–68. https://doi.org/10.1177/0269881114555249 First citation in articleCrossref, Google Scholar

  • Girn, M., Mills, C., Roseman, L., Carhart-Harris, R. L., & Christoff, K. (2020). Updating the dynamic framework of thought: Creativity and psychedelics. NeuroImage, 213, Article 116726. First citation in articleCrossref, Google Scholar

  • Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020). Integrating psychotherapy and psychopharmacology: Psychedelic-assisted psychotherapy and other combined treatments. Expert Review of Clinical Pharmacology, 13, 655–670. https://doi.org/10.1080/17512433.2020.1772054 First citation in articleCrossref, Google Scholar

  • Greicius, M. D., Flores, B. H., Menon, V., Glover, G. H., Solvason, H. B., Kenna, H., & Schatzberg, A. F. (2007). Resting-state functional connectivity in major depression: Abnormally increased contributions from subgenual cingulate cortex and thalamus. Biological Psychiatry, 62(5), 429–437. https://doi.org/10.1016/j.biopsych.2006.09.020 First citation in articleCrossref, Google Scholar

  • Griffiths, R. R., Hurwitz, E. S., Davis, A. K., Johnson, M. W., & Jesse, R. (2019). Survey of subjective “God encounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS One, 14(4), Article e0214377. https://doi.org/10.1371/journal.pone.0214377 First citation in articleCrossref, Google Scholar

  • Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30, 1181–1197. https://doi.org/10.1177/0269881116675513 First citation in articleCrossref, Google Scholar

  • Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011). Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology, 218(4), 649–665. https://doi.org/10.1007/s00213-011-2358-5 First citation in articleCrossref, Google Scholar

  • Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018). Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology, 32, 49–69. https://doi.org/10.1177/0269881117731279 First citation in articleCrossref, Google Scholar

  • Griffiths, R. R., Richards, W. A., Johnson, M., McCann, U., & Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology, 22(6), 621–632. https://doi.org/10.1177/0269881108094300 First citation in articleCrossref, Google Scholar

  • Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268–283. https://doi.org/10.1007/s00213-006-0457-5 First citation in articleCrossref, Google Scholar

  • Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry, 68(1), 71–78. https://doi.org/10.1001/archgenpsychiatry.2010.116 First citation in articleCrossref, Google Scholar

  • Halpern, J. H., Lerner, A. G., & Passie, T. (2016). A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. In A. HalberstadtF. X. VollenweiderD. E. NicholsEds., Behavioral neurobiology of psychedelic drugs (pp. 333–360). Springer. First citation in articleCrossref, Google Scholar

  • Hamilton, J. P., Farmer, M., Fogelman, P., & Gotlib, I. H. (2015). Depressive rumination, the default-mode network, and the dark matter of clinical neuroscience. Biological Psychiatry, 78(4), 224–230. https://doi.org/10.1016/j.biopsych.2015.02.020 First citation in articleCrossref, Google Scholar

  • Harman, W. W., McKim, R. H., Mogar, R. E., Fadiman, J., & Stolaroff, M. J. (1966). Psychedelic agents in creative problem-solving: A pilot study. Psychological Reports, 19, 211–227. First citation in articleCrossref, Google Scholar

  • Hartogsohn, I. (2016). Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Journal of Psychopharmacology, 30(12), 1259–1267. https://doi.org/10.1177/0269881116677852 First citation in articleCrossref, Google Scholar

  • Hendricks, P. S., Clark, C. B., Johnson, M. W., Fontaine, K. R., & Cropsey, K. L. (2014). Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. Journal of Psychopharmacology, 28(1), 62–66. https://doi.org/10.1177/0269881113513851 First citation in articleCrossref, Google Scholar

  • Hendricks, P. S., Crawford, M. S., Cropsey, K. L., Copes, H., Sweat, N. W., Walsh, Z., & Pavela, G. (2018). The relationships of classic psychedelic use with criminal behavior in the United States adult population. Journal of Psychopharmacology, 32(1), 37–48. https://doi.org/10.1177/0269881117735685 First citation in articleCrossref, Google Scholar

  • Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. (2015). Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology, 29(3), 280–288. https://doi.org/10.1177/0269881114565653 First citation in articleCrossref, Google Scholar

  • Hermle, L., Simon, M., Ruchsow, M., & Geppert, M. (2012). Hallucinogen-persisting perception disorder. Therapeutic Advances in Psychopharmacology, 2, 199–205. First citation in articleCrossref, Google Scholar

  • Heuschkel, K., & Kuypers, K. (2020). Depression, mindfulness, and psilocybin: Possible complementary effects of mindfulness meditation and psilocybin in the treatment of depression. A review. Frontiers in Psychiatry, 11, Article 224. https://doi.org/10.3389/fpsyt.2020.00224 First citation in articleCrossref, Google Scholar

  • Johansen, P. O., & Krebs, T. S. (2015). Psychedelics not linked to mental health problems or suicidal behavior: A population study. Journal of Psychopharmacology, 29(3), 270–279. https://doi.org/10.1177/0269881114568039 First citation in articleCrossref, Google Scholar

  • Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse, 43, 55–60. First citation in articleCrossref, Google Scholar

  • Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983–992. https://doi.org/10.1177/0269881114548296 First citation in articleCrossref, Google Scholar

  • Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology and Therapeutics, 197, 83–102. First citation in articleCrossref, Google Scholar

  • Johnson, M., Richards, W., & Griffiths, R. (2008). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology, 22(6), 603–620. https://doi.org/10.1177/0269881108093587 First citation in articleCrossref, Google Scholar

  • Kangaslampi, S., Hausen, A., & Rauteenmaa, T. (2020). Mystical experiences in retrospective reports of first times using a psychedelic in Finland. Journal of Psychoactive Drugs, 52, 309–318. First citation in articleCrossref, Google Scholar

  • Kettner, H., Gandy, S., Haijen, E. C., & Carhart-Harris, R. L. (2019). From egoism to ecoism: Psychedelics increase nature relatedness in a state-mediated and context-dependent manner. International Journal of Environmental Research and Public Health, 16(24), Article 5147. https://doi.org/10.3390/ijerph16245147 First citation in articleCrossref, Google Scholar

  • Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015). Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biological Psychiatry, 78, 572–581. First citation in articleCrossref, Google Scholar

  • Krebs, T. S., & Johansen, P.-Ø. (2012). Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. Journal of Psychopharmacology, 26, 994–1002. First citation in articleCrossref, Google Scholar

  • Krebs, T. S., & Johansen, P.-Ø. (2013). Psychedelics and mental health: A population study. PLoS One, 8, Article e63972. First citation in articleCrossref, Google Scholar

  • Kuypers, K. P. C., Riba, J., De La Fuente Revenga, M., Barker, S., Theunissen, E. L., & Ramaekers, J. G. (2016). Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. Psychopharmacology, 233(18), 3395–3403. https://doi.org/10.1007/s00213-016-4377-8 First citation in articleCrossref, Google Scholar

  • Lebedev, A. V., Kaelen, M., Lövdén, M., Nilsson, J., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2016). LSD-induced entropic brain activity predicts subsequent personality change. Human Brain Mapping, 37(9), 3203–3213. https://doi.org/10.1002/hbm.23234 First citation in articleCrossref, Google Scholar

  • Liechti, M. E., Dolder, P. C., & Schmid, Y. (2017). Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology, 234(9–10), 1499–1510. https://doi.org/10.1007/s00213-016-4453-0 First citation in articleCrossref, Google Scholar

  • Lyons, T., & Carhart-Harris, R. L. (2018). Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. Journal of Psychopharmacology, 32(7), 811–819. https://doi.org/10.1177/0269881117748902 First citation in articleCrossref, Google Scholar

  • MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology, 25(11), 1453–1461. https://doi.org/10.1177/0269881111420188 First citation in articleCrossref, Google Scholar

  • Madsen, M. K., Fisher, P. M., Stenbæk, D. S., Kristiansen, S., Burmester, D., Lehel, S., Páleníček, T., Kuchař, M., Svarer, C., Ozenne, B., & Knudsen, G. M. (2020). A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 33, 71–80. https://doi.org/10.1016/j.euroneuro.2021.06.001 First citation in articleCrossref, Google Scholar

  • Mitchell, A. J., Chan, M., & Bhatt, H. (2011). Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interview-based studies. The Lancet Oncology, 12(2), 160–174. https://doi.org/10.1016/s1470-2045(11)70002-x First citation in articleCrossref, Google Scholar

  • Muttoni, S., Ardissino, M., & John, C. (2019). Classical psychedelics for the treatment of depression and anxiety: A systematic review. Journal of Affective Disorders, 258, 11–24. https://doi.org/10.1016/j.jad.2019.07.076 First citation in articleCrossref, Google Scholar

  • Nichols, D. E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101, 131–181. First citation in articleCrossref, Google Scholar

  • Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68, 264–355. First citation in articleCrossref, Google Scholar

  • Nisbet, E. K., Zelenski, J. M., & Murphy, S. A. (2011). Happiness is in our nature: Exploring nature relatedness as a contributor to subjective well-being. Journal of Happiness Studies, 12(2), 303–322. https://doi.org/10.1007/s10902-010-9197-7 First citation in articleCrossref, Google Scholar

  • Nour, M. M., Evans, L., & Carhart-Harris, R. L. (2017). Psychedelics, personality and political perspectives. Journal of Psychoactive Drugs, 49(3), 182–191. https://doi.org/10.1080/02791072.2017.1312643 First citation in articleCrossref, Google Scholar

  • Nutt, D. J., King, L. A., & Nichols, D. E. (2013). Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Reviews: Neuroscience, 14(8), 577–585. https://doi.org/10.1038/nrn3530 First citation in articleCrossref, Google Scholar

  • Nutt, D. J., King, L. A., Saulsbury, W., & Blakemore, C. (2007). Development of a rational scale to assess the harm of drugs of potential misuse. The Lancet, 369(9566), 1047–1053. https://doi.org/10.1016/s0140-6736(07)60464-4 First citation in articleCrossref, Google Scholar

  • Osório, F., Sanches, R. F., Macedo, L. R., Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015). Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report. Brazilian Journal of Psychiatry, 37, 13–20. https://doi.org/10.1590/1516-4446-2014-1496 First citation in articleCrossref, Google Scholar

  • Pahnke, W. N., Kurland, A. A., Unger, S., Savage, C., & Grof, S. (1970). The experimental use of psychedelic (LSD) psychotherapy. Journal of American Medical Association, 212, 1856–1863. First citation in articleCrossref, Google Scholar

  • Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., Dos Santos, R. G., Tófoli, L. F., de Oliveira Silveira, G., Yonamine, M., Riba, J., Santos, F. R., Silva-Junior, A. A., Alchieri, J. C., Galvão-Coelho, N. L., Lobão-Soares, B., … Araújo, D. B. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychological Medicine, 49, 655–663. https://doi.org/10.1017/s0033291718001356 First citation in articleCrossref, Google Scholar

  • Pisano, V. D., Putnam, N. P., Kramer, H. M., Franciotti, K. J., Halpern, J. H., & Holden, S. C. (2017). The association of psychedelic use and opioid use disorders among illicit users in the United States. Journal of Psychopharmacology, 31(5), 606–613. https://doi.org/10.1177/0269881117691453 First citation in articleCrossref, Google Scholar

  • Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003). Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics, 306(1), 73–83. https://doi.org/10.1124/jpet.103.049882 First citation in articleCrossref, Google Scholar

  • Romeo, B., Karila, L., Martelli, C., & Benyamina, A. (2020). Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis. Journal of Psychopharmacology, 34, 1079–1085. https://doi.org/10.1177/0269881120919957 First citation in articleCrossref, Google Scholar

  • Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R. (2019). Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. Journal of Psychopharmacology, 33(9), 1076–1087. https://doi.org/10.1177/0269881119855974 First citation in articleCrossref, Google Scholar

  • Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in Pharmacology, 8, Article 974. https://doi.org/10.3389/fphar.2017.00974 First citation in articleCrossref, Google Scholar

  • Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30, 1165–1180. https://doi.org/10.1177/0269881116675512 First citation in articleCrossref, Google Scholar

  • Rucker, J. J., Jelen, L. A., Flynn, S., Frowde, K. D., & Young, A. H. (2016). Psychedelics in the treatment of unipolar mood disorders: A systematic review. Journal of Psychopharmacology, 30(12), 1220–1229. https://doi.org/10.1177/0269881116679368 First citation in articleCrossref, Google Scholar

  • Sanches, R. F., de Lima Osório, F., Dos Santos, R. G., Macedo, L. R., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2016). Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A SPECT study. Journal of Clinical Psychopharmacology, 36(1), 77–81. https://doi.org/10.1097/jcp.0000000000000436 First citation in articleCrossref, Google Scholar

  • Sessa, B. (2008). Is it time to revisit the role of psychedelic drugs in enhancing human creativity? Journal of Psychopharmacology, 22(8), 821–827. https://doi.org/10.1177/0269881108091597 First citation in articleCrossref, Google Scholar

  • Sessa, B., & Fischer, F. M. (2015). Underground MDMA-, LSD-and 2-CB-assisted individual and group psychotherapy in Zürich: Outcomes, implications and commentary. Drug Science, Policy and Law, 2, 1–8. First citation in articleCrossref, Google Scholar

  • Sessa, B., & Johnson, M. W. (2015). Can psychedelic compounds play a part in drug dependence therapy? The British Journal of Psychiatry, 206(1), 1–3. https://doi.org/10.1192/bjp.bp.114.148031 First citation in articleCrossref, Google Scholar

  • Sheline, Y. I., Barch, D. M., Price, J. L., Rundle, M. M., Vaishnavi, S. N., Snyder, A. Z., Mintun, M. A., Wang, S., Coalson, R. S., & Raichle, M. E. (2009). The default mode network and self-referential processes in depression. Proceedings of the National Academy of Sciences of the United States of America, 106, 1942–1947. https://doi.org/10.1073/pnas.0812686106 First citation in articleCrossref, Google Scholar

  • Smith, C. M. (1958). A new adjunct to the treatment of alcoholism: The hallucinogenic drugs. Quarterly Journal of Studies on Alcohol, 19(3), 406–417. First citation in articleCrossref, Google Scholar

  • Soler, J., Elices, M., Franquesa, A., Barker, S., Friedlander, P., Feilding, A., Pascual, J. C., & Riba, J. (2016). Exploring the therapeutic potential of ayahuasca: Acute intake increases mindfulness-related capacities. Psychopharmacology, 233, 823–829. https://doi.org/10.1007/s00213-015-4162-0 First citation in articleCrossref, Google Scholar

  • Speth, J., Speth, C., Kaelen, M., Schloerscheidt, A. M., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2016). Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. Journal of Psychopharmacology, 30(4), 344–353. https://doi.org/10.1177/0269881116628430 First citation in articleCrossref, Google Scholar

  • Sweat, N. W., Bates, L. W., & Hendricks, P. S. (2016). The associations of naturalistic classic psychedelic use, mystical experience, and creative problem solving. Journal of Psychoactive Drugs, 485, 344–350. First citation in articleCrossref, Google Scholar

  • Tagliazucchi, E., Carhart-Harris, R., Leech, R., Nutt, D., & Chialvo, D. R. (2014). Enhanced repertoire of brain dynamical states during the psychedelic experience. Human Brain Mapping, 35(1), 5442–5456. https://doi.org/10.1002/hbm.22562 First citation in articleCrossref, Google Scholar

  • Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., Laufs, H., Leech, R., McGonigle, J., Crossley, N., Bullmore, E., Williams, T., Bolstridge, M., Feilding, A., Nutt, D. J., & Carhart-Harris, R. (2016). Increased global functional connectivity correlates with LSD-induced ego dissolution. Current Biology, 26(8), 1043–1050. https://doi.org/10.1016/j.cub.2016.02.010 First citation in articleCrossref, Google Scholar

  • Thiessen, M. S., Walsh, Z., Bird, B. M., & Lafrance, A. (2018). Psychedelic use and intimate partner violence: The role of emotion regulation. Journal of Psychopharmacology, 32(7), 749–755. https://doi.org/10.1177/0269881118771782 First citation in articleCrossref, Google Scholar

  • Uher, R., & Pavlova, B. (2016). Long-term effects of depression treatment. The Lancet Psychiatry, 3(2), 95–96. https://doi.org/10.1016/s2215-0366(15)00578-7 First citation in articleCrossref, Google Scholar

  • Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nature Reviews: Neuroscience, 11(9), 642–651. https://doi.org/10.1038/nrn2884 First citation in articleCrossref, Google Scholar

  • Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. Journal of Humanistic Psychology, 57(5), 520–564. https://doi.org/10.1177/0022167817709585 First citation in articleCrossref, Google Scholar

  • Yaden, D. B., Le Nguyen, K. D., Kern, M. L., Belser, A. B., Eichstaedt, J. C., Iwry, J., Smith, M. E., Wintering, N. A., Hood, R. W., & Newberg, A. B. (2017). Of roots and fruits: A comparison of psychedelic and nonpsychedelic mystical experiences. Journal of Humanistic Psychology, 57(4), 338–353. https://doi.org/10.1177/0022167816674625 First citation in articleCrossref, Google Scholar

  • Yockey, R. A., King, K. A., & Vidourek, R. A. (2019). “Go ask Alice, when she’s 10-feet tall”: Psychosocial correlates to lifetime LSD use among a national sample of US adults. Journal of Psychedelic Studies, 3, 308–314. First citation in articleCrossref, Google Scholar